There is no doubt that we experience exciting times, with regard to the management of lung cancer. The production of new knowledge over the last years is so fast that the clinicians often find it difficult to engulf. This is particular true in the area of basic science, where our understanding of carcinogenesis and tumor development has significantly increased, providing the potential of earlier diagnosis, more effective treatments and finally better prognosis of lung cancer patients. Nevertheless the “translation” of our recently acquired knowledge from the lab bench to the bedside is neither smooth and nor without obstructions, due to the existing “gaps” in our understanding and the often contradictory “signals” from clinical trials.
In this educational course we will provide treating physicians with practical information regarding the clinical significance of the histological and molecular profile of the tumor and how its integration in the therapeutic algorithm changes the clinical practice. International faculty members will present the latest clinical data regarding the implementation of targeted therapies on lung cancer. Finally we will set the pavement for the future research and strategies towards the personalized treatment lung cancer patients.
Consequently, the targeted audience includes:
The Chairs of the meeting:
Kostas Syrigos Rolf Stahel
Lungcancer 2012 Invitation to attend